<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> infiltration with effector CD8(+) T cells (T(eff)) predicts longer recurrence-free survival in many types of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, illustrating the broad significance of T(eff) for effective immunosurveillance </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">Colorectal tumors</z:e> with reduced accumulation of T(eff) express low levels of T(eff)-attracting chemokines such as CXCL10/IP10 and CCL5/RANTES </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we investigated the feasibility of enhancing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> production of T(eff)-attracting chemokines as a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapeutic strategy using a tissue explant culture system to analyze chemokine induction in intact <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues </plain></SENT>
<SENT sid="3" pm="."><plain>In different <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> explants, we observed highly <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> responses to IFNα or poly-I:C (a TLR3 ligand) when they were applied individually </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, a combination of IFNα and poly-I:C uniformly enhanced the production of CXCL10 and CCL5 in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lesions </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, these effects could be optimized by the further addition of COX inhibitors </plain></SENT>
<SENT sid="6" pm="."><plain>Applying this triple combination also uniformly suppressed the production of CCL22/MDC, a chemokine associated with infiltration of T regulatory cells (T(reg)) </plain></SENT>
<SENT sid="7" pm="."><plain>The T(eff)-enhancing effects of this treatment occurred selectively in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues, as compared with tissues derived from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> margins </plain></SENT>
<SENT sid="8" pm="."><plain>These effects relied on the increased propensity of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated cells (mostly fibroblasts and infiltrating inflammatory cells) to hyperactivate NF-κB and produce T(eff)-attracting chemokines in response to treatment, resulting in an enhanced ability of the treated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> to attract T(eff) cells and reduced ability to attract T(reg) cells </plain></SENT>
<SENT sid="9" pm="."><plain>Together, our findings suggest the feasibility of exploiting NF-κB hyperactivation in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment to selectively enhance T(eff) entry into <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumors</z:e> </plain></SENT>
</text></document>